Robert Sidonio on the Role of aPCC in Patients Receiving Emicizumab Prophylaxis
Robert Sidonio, Professor of Pediatrics at Emory University Hospital, shared a post on LinkedIn:
”It is our great pleasure to share that our publication “Activated Prothrombin Complex Concentrate in Patients Receiving Emicizumab Prophylaxis: From Evidence to Clinical Practice” is now available for free access online as Pre-proof. Thanks to Takeda for organizing this awesome group of hematologists!”
Read the full article here.
In the recently published article ‘Activated Prothrombin Complex Concentrate in Patients Receiving Emicizumab Prophylaxis: From Evidence to Clinical Practice‘ by Robert F. Sidonio Jr. et al., in the RPTH Journal, the role of Activated Prothrombin Complex Concentrate in patients receiving Emicizumab prophyaxis is discussed.
Stay updated on the latest scientific advancements in the filed with Hemostasis Today.
-
Sep 10, 2026, 05:12Douglas S. Campbell: Great to See a Strong Japanese Presence in 2026 Lasker Awards
-
Sep 10, 2026, 05:11Jan Hartmann: New Transformative Treatment for Hemophilia A
-
Sep 10, 2026, 05:09Shelby Bradford: Award-Winning Science Incoming
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH